Abeona TherapeuticsABEO
ABEO
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Employees: 136
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,505% more call options, than puts
Call options by funds: $2.86M | Put options by funds: $178K
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
9% more funds holding
Funds holding: 64 [Q4 2024] → 70 (+6) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
9.3% less ownership
Funds ownership: 70.44% [Q4 2024] → 61.14% (-9.3%) [Q1 2025]
17% less capital invested
Capital invested by funds: $170M [Q4 2024] → $141M (-$29.2M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
144%
upside
Avg. target
$18.50
200%
upside
High target
$20
225%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Andreas Argyrides | 208%upside $19 | Outperform Assumed | 2 Jun 2025 |
Stifel Dae Gon Ha | 225%upside $20 | Buy Maintained | 16 May 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 225%upside $20 | Buy Maintained | 30 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor | 144%upside $15 | Buy Reiterated | 24 Mar 2025 |
Financial journalist opinion
Based on 4 articles about ABEO published over the past 30 days
Positive
Seeking Alpha
1 week ago
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market, especially after a $152 million PRV sale bolstered cash reserves. Conservative launch modeling, including risk-adjusted revenue and single-treatment assumptions, still yields a fair value 36%+ above the current share price. Execution of outcome-based payer agreements and a strong cash position de-risk the launch, while competition and reimbursement remain manageable concerns.
Neutral
GlobeNewsWire
1 week ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 weeks ago
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time.
Neutral
Seeking Alpha
1 month ago
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Greg Gin - Vice President-Investor Relations and Communications Vish Seshadri - Chief Executive Officer Madhav Vasanthavada - Chief Commercial Officer and Head-Business Development Brian Kevany - Chief Technical Officer Joe Vazzano - Chief Financial Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Steven Willey - Stifel Ram Selvaraju - H.C. Wainwright James Molloy - Alliance Global Partners David Bautz - Zacks Small Cap Research Operator Good day and welcome to the Abeona Therapeutics First Quarter 2025 Conference Call.
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC) - - Entered into sales agreement for priority review voucher (PRV) for $155 million - CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational progress. “ZEVASKYN's approval just a few weeks ago is a landmark achievement for recessive dystrophic epidermolysis bullosa patients and signifies Abeona's transition to a commercial-stage cell and gene therapy company,” said Vish Seshadri, Chief Executive Officer of Abeona.
Neutral
GlobeNewsWire
1 month ago
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment - - Abeona Assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout ZEVASKYN treatment journey - CLEVELAND and CHICAGO, May 14, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Ann & Robert H.
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration (FDA) approval of ZEVASKYN™ (prademagene zamikeracel) on April 28, 2025.
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, May 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™